Latest Company Filings News

Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.

Nanollose Limited reported a $1.53 million loss for the half-year ending December 2025, while advancing its proprietary lyocell fibre pilot production and expanding its intellectual property portfolio.

Arovella Therapeutics reported a 22% increase in half-year losses to $1.88 million while securing FDA acceptance of its IND application for lead asset ALA-101, paving the way for first-in-human trials.

5E Advanced Materials has filed a Post-Effective Amendment to its SEC registration, updating the legal opinion on its planned issuance of up to 18 million shares. This move clears a key regulatory step in the company’s capital raising journey.

5E Advanced Materials has filed an SEC amendment to increase its public offering by $6 million, signalling a strategic move to bolster its capital base.

5E Advanced Materials has filed a Form S-1 registration with the SEC to raise up to $30 million through a common stock offering, aiming to advance its Fort Cady boron and lithium project. The capital raise is critical as the company navigates development milestones and financial challenges.

Sarama Resources has raised A$2.7 million to fund exploration at its Australian gold projects while progressing a significant arbitration claim against Burkina Faso for expropriation of its African permit.

Sarama Resources Ltd reported a $1.9 million loss for the first nine months of 2025 while securing A$2.7 million in equity funding and advancing a $242 million arbitration claim against Burkina Faso over mining permit expropriation.

Cassius Mining Limited reports steady progress on its Soalara Limestone Project joint venture discussions and updates on its international arbitration case against Ghana, while raising $250,000 through share and convertible note issuances.

Race Oncology has uncovered that its anticancer drug bisantrene exists as three light-sensitive isomers, with only one showing potent activity. The company has filed patents to protect this active form, potentially extending its intellectual property rights until 2045.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

Li-S Energy Limited reported a $6.41 million net loss for FY25 while making significant strides in commercialising its lithium-sulfur battery technology, including commissioning new production facilities and securing key strategic partnerships.